相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy, Safety, Tolerability, and Pharmacokinetic Profile of Evacetrapib Administered as Monotherapy or in Combination With Atorvastatin in Japanese Patients With Dyslipidemia
Tamio Teramoto et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Lipoprotein(a): Fasting and nonfasting levels, inflammation, and cardiovascular risk
Anne Langsted et al.
ATHEROSCLEROSIS (2014)
Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Amit V. Khera et al.
CIRCULATION (2014)
The Therapeutic Role of Niacin in Dyslipidemia Management
William E. Boden et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2014)
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The influence of regular walking at different times of day on blood lipids and inflammatory markers in sedentary patients with coronary artery disease
Xiao-Qing Lian et al.
PREVENTIVE MEDICINE (2014)
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study
Barbara Sjouke et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia
Elisavet Moutzouri et al.
ATHEROSCLEROSIS (2013)
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia
Tamio Teramoto et al.
ATHEROSCLEROSIS (2013)
Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease Prospective Observational Multicenter Study
Josef Leebmann et al.
CIRCULATION (2013)
AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial
Nihar R. Desai et al.
CIRCULATION (2013)
Efficacy and Safety of Morning Versus Evening Dose of Controlled-Release Simvastatin Tablets in Patients With Hyperlipidemia: A Randomized, Double-Blind, Multicenter Phase III Trial
Sang-Hyun Kim et al.
CLINICAL THERAPEUTICS (2013)
Niacin: a long history, but a questionable future
Henry N. Ginsberg et al.
CURRENT OPINION IN LIPIDOLOGY (2013)
Estrogens and cardiovascular disease risk revisited: the Women's Health Initiative
Barbara V. Howard et al.
CURRENT OPINION IN LIPIDOLOGY (2013)
Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial
Anastazia Kei et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2013)
Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction
Michael H. Davidson
JOURNAL OF CLINICAL LIPIDOLOGY (2013)
Lipoprotein(a): resurrected by genetics
F. Kronenberg et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
Gregory S. Thomas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes)
John J. Albers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
The Current State of Niacin in Cardiovascular Disease Prevention A Systematic Review and Meta-Regression
Paul M. Lavigne et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
Marina Cuchel et al.
LANCET (2013)
The Effect of an Energy Restricted Low Glycemic Index Diet on Blood Lipids, Apolipoproteins and Lipoprotein (a) Among Adolescent Girls with Excess Weight: a Randomized Clinical Trial
Mohammad Hossein Rouhani et al.
LIPIDS (2013)
Lipoprotein(a), Cardiovascular Disease, and Contemporary Management
Terry A. Jacobson
MAYO CLINIC PROCEEDINGS (2013)
Lipoprotein(a) metabolism: Potential sites for therapeutic targets
Jane Hoover-Plow et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Genetic Associations with Valvular Calcification and Aortic Stenosis
George Thanassoulis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study
Kishor M. Wasan et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial
Frederick Raal et al.
CIRCULATION (2012)
Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia
Evan A. Stein et al.
CIRCULATION (2012)
Niacin: The Evidence, Clinical Use, and Future Directions
Todd C. Villines et al.
CURRENT ATHEROSCLEROSIS REPORTS (2012)
The effects of resistance training on ApoB/ApoA-I ratio, Lp(a) and inflammatory markers in patients with type 2 diabetes
Nikolaos P. E. Kadoglou et al.
ENDOCRINE (2012)
Role of thyroid receptor β in lipid metabolism
Camilla Pramfalk et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Pia R. Kamstrup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Robert Clarke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial
S Tsimikas et al.
CIRCULATION (2004)
分享论文
